News & Updates

Show Multimedia Only
VTE incidence similar among common SGAs
VTE incidence similar among common SGAs
05 Sep 2024

The incidence of venous thromboembolism (VTE) does not appear to significantly differ among patients treated with second-generation antipsychotics (SGAs) such as risperidone, olanzapine, or aripiprazole, results of a study have shown.

VTE incidence similar among common SGAs
05 Sep 2024
Colchicine on par with NSAID for pericarditis prevention in HFrEF, CAD
Colchicine on par with NSAID for pericarditis prevention in HFrEF, CAD
04 Sep 2024
Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
04 Sep 2024 byAudrey Abella

In older patients with untreated mantle cell lymphoma (MCL), the addition of the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to bendamustine and rituximab (ABR) conferred a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a favourable trend for overall survival (OS), findings from the phase III ECHO trial have shown.

Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
04 Sep 2024
Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
01 Sep 2024 byJairia Dela Cruz

In the treatment of patients with early oligoarticular psoriatic arthritis (PsA), the use of apremilast yields substantial improvements in both clinical and patient-reported outcomes, as shown in the results of the phase IV FOREMOST study.

Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
01 Sep 2024